Recombinant Human TAPBPR Fc Chimera Protein, CF

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion by human T cells. The ED50 for this effect 0.500‑10.0 μg/mL.

2 μg/lane of Recombinant Human TAPBPR Fc Chimera Protein (Catalog # 11171-TP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-90 kDa and 150-180 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TAPBPR Fc Chimera Protein, CF Summary

• Additional Information: (CHO-expressed)
• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 0.500‑10.0 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human TAPBPR protein
  

  Human TAPBPR (Ala19-Arg404) Accession # Q9BX59.2	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q9BX59.2
• N-terminal Sequence: Ala19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.50 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 68 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75-90 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TAPBPR Fc Chimera Protein, CF

• FLJ10143
• TAP binding protein-like
• Tapasin Related Protein/TAPBPR
• Tapasin-like
• TAPASIN-R
• tapasin-related protein
• TAP-binding protein-like
• TAP-binding protein-related protein
• TAPBPL
• TAPBPR
• TAPBP-RTAP binding protein related
• TAPBPRtapasin-like

Background

TAP-binding protein-like (TAPBPL), also known as TAP binding protein-related (TAPBPR) and Tapasin-related protein (TAPASINR) is a transmembrane protein of the Immunoglobulin (Ig) superfamily (1, 2). TAPBPR was originally isolated as a homologue to TAPASIN but more recently was identified as a novel B7 family-related molecule since it shares sequence, structural, and functional similarities to B7 family members (3). Mature human TAPBPR consists of a lumenal domain containing an IgV and IgC domain, a transmembrane domain, and a cytoplasmic tail which lacks an ER retention motif. Within the lumenal domain, mature human TAPBPR shares 70% and 71% amino acid sequence identity with mouse and rat TAPBPR, respectively. Multiple alternatively spliced TAPBPR isoforms are known to exist with unique properties (4).TAPBPR is widely expressed and, similar to TAPASIN, functions as a both a chaperone protein and peptide editor of MHC class I, but in a peptide‑loading complex (PLC) independent manner (5, 6). TAPBPR decreases the rate at which MHC class I molecules mature through the secretory pathway, a role which could be important for peptide selection by MHC class I molecules (7). TAPBPR is also expressed on the surface of T cells and antigen-presenting cells (APCs) and plays an inhibitory role in the proliferation and activation of T cells (4). TAPBPR can be expressed on various cancer cells like leukemia and has the potential to be used in the treatment of autoimmune diseases and transplant rejection, as well as cancer (4).

1. Hermann, C. et al. (2015) Tissue antigens 85(3):155.
2. Teng, M. et al. (2002) European Journal of Immunology 32:1059.
3. Lin, Y. et al. (2021). EMBO Mol Med. 13(5):13404.
4. Porter, K.M. et al. (2014) Immunology 142:289.
5. Margulies, D. et al. (2020) Current Opinion in Immunology 64:71.
6. Boyle, L.H. et al. (2013) PNAS 110:3465.
7. Hermann, C. et al. (2013) Journal of Immunology 191(11):5743.

Bioinformatics

• Uniprot:
  • Q9BX59.2()